NADPH Oxidase NOX2 Defines a New Antagonistic Role for Reactive Oxygen Species and cAMP/PKA in the Regulation of Insulin Secretion

Ning Li; Bin Li; Brun, Thierry; Deffert-Delbouille, Christine; Mahiout, Zahia; Daali, Youssef; Xiao-Juan Ma; Krause, Karl-Heinz; Maechler, Pierre
November 2012
Diabetes;Nov2012, Vol. 61 Issue 11, p2842
Academic Journal
In insulin-secreting cells, expression of NADPH oxidase (NOX), a potent source of ROS, has been reported, along with controversial findings regarding its function. Here, the role of NOXs was investigated: first by expression and cellular localization in mouse and human pancreatic islets, and then by functional studies in islets isolated from Nox isoform-specific knockout mice. Both human and mouse β-cells express NOX, in particular NOX2. With use of Nox isoform-specific knockout mice, functional analysis revealed Nox2 as the predominant isoform. In human islets, NOX2 colocalized with both insulin granules and endosome/lysosome membranes. Nox2-deficient islets stimulated with 22.8 mmol/L glucose exhibited potentiation of insulin release compared with controls, an effect confirmed with in vitro knockdown of Nox2. The enhanced secretory function in Nox2-deficient islets was associated with both lower superoxide levels and elevated cAMP concentrations. In control islets, GLP-1 and other cAMP inducers suppressed glucose-induced ROS production similarly to Nox2 deficiency. Inhibiting cAMP-dependent protein kinase reduced the secretory response in Nox2-null islets, although not in control islets. This study ascribes a new role for NOX2 in pancreatic β-cells as negative modulator of the secretory response, reducing cAMP/PKA signaling secondary to ROS generation. Results also show reciprocal inhibition between the cAMP/PKA pathway and ROS.


Related Articles

  • Comparison of tests of beta-cell function across a range of glucose tolerance from normal to diabetes. Hermans, Michel P.; Levy, Jonathan C.; Morris, Richard J.; Turner, Robert C.; Hermans, M P; Levy, J C; Morris, R J; Turner, R C // Diabetes;Sep99, Vol. 48 Issue 9, p1779 

    Adequate comparisons of the relative performance of different tests of beta-cell function are not available. We compared discrimination of commonly used in vivo tests of beta-cell function across a range of glucose tolerance in seven subjects with normal glucose tolerance (NGT), eight subjects...

  • Preservation of Pancreatic β-Cell Function and Prevention of Type 2 Diabetes by Pharmacological Treatment of Insulin Resistance in High-Risk Hispanic Women. Buchanan, Thomas A.; Xiang, Anny H.; Peters, Ruth K.; Kjos, Siri L.; Marroquin, Aura; Goico, Jose; Ochoa, Cesar; Tan, Sylvia; Berkowitz, Kathleen; Hodis, Howard N.; Azen, Stanley P. // Diabetes;Sep2002, Vol. 51 Issue 9, p2796 

    Type 2 diabetes frequently results from progressive failure of pancreatic β-cell function in the presence of chronic insulin resistance. We tested whether chronic amelioration of insulin resistance would preserve pancreatic β-cell function and delay or prevent the onset of type 2 diabetes...

  • BETA CELL DEVELOPMENT AND POSTNATAL GROWTH.  // Diabetes;Jun 2014 Supplement, pA52 

    The article presents abstracts of studies related to beta cell development and postnatal growth, which include the role of unfolded protein response (UPR) in beta cell proliferation, the association of insulin gene transactivator GLIS3 with beta-cell mass expansion and insulin sensitivity, and...

  • Erratum.  // Diabetes;Jan2015, Vol. 64 Issue 1, p312 

    A correction to the article titled "Bimodal Effect on Pancreatic Beta-Cell of Secretory Products from Normal or Insulin-Resistant Human Skeletal Muscle" that was published in a 2011 issue of "Diabetes" is presented.

  • Longitudinal compensation for fat-induced insulin resistance includes reduced insulin clearance and enhanced beta-cell response. Mittelman, Steven D.; Van Citters, Gregg W.; Kim, Stella P.; Davis, Doug A.; Dea, Melvin K.; Hamilton-Wessler, Marianthe; Bergman, Richard N.; Mittelman, S D; Van Citters, G W; Kim, S P; Davis, D A; Dea, M K; Hamilton-Wessler, M; Bergman, R N // Diabetes;Dec2000, Vol. 49 Issue 12, p2116 

    Central adiposity is highly correlated with insulin resistance, which is an important risk factor for type 2 diabetes and other chronic diseases. However, in normal individuals, central adiposity can be tolerated for many years without development of impaired glucose tolerance or diabetes. Here...

  • A Novel Antidiabetic Drug, Troglitazone – Reason for Hope and Concern. Imura, Hiroo // New England Journal of Medicine;03/26/98, Vol. 338 Issue 13, p908 

    The author discusses how Type II (non-insulin-dependent) diabetes mellitus is characterized by insulin resistance, increased hepatic glucose production, and impaired secretion of insulin by pancreatic beta cells. Although the primary defect underlying these abnormalities is still not known,...

  • Insulin secretion: movement at all levels. Henquin, Jean-Claude; Boitard, Christian; Efendic, Suad; Ferrannini, Ele; Steiner, Donald F.; Cerasi, Erol // Diabetes;Feb2002 Supplement, Vol. 51, pS1 

    Editorial. Examines the effects of insulin resistance on type two diabetes. Increase of cytosolic beta-cells; Decrease of hyperglycemia; Release of the glucose metabolism.

  • Accurate Assessment of β-Cells Function. Bergman, Richard N.; Ader, Marilyn; Huecking, Katrin; Van Citters, Gregg // Diabetes;Feb2002 Supplement, Vol. 51, pS212 

    Only in the last decade did modeling studies predict, and knockout experiments confirm, that type 2 diabetes is a “2-hit” disease in which insulin resistance is necessarily accompanied by β-cell defect(s) preventing the compensatory upregulation of insulin secretion. This...

  • Phloridzin improves hyperglycemia but not hepatic insulin resistance in a transgenic mouse model of type 2 diabetes. Zhao, Hong; Yakar, Shoshana; Gavrilova, Oksana; Sun, Hui; Zhang, Yang; Kim, Hyunsook; Setser, Jennifer; Jou, William; LeRoith, Derek // Diabetes;Nov2004, Vol. 53 Issue 11, p2901 

    The chronic hyperglycemia that occurs in type 2 diabetes may cause deterioration of beta-cell function and insulin resistance in peripheral tissues. Mice that express a dominant-negative IGF-1 receptor, specifically in skeletal muscle (MKR mice), exhibit severe insulin resistance,...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics